{"id":55791,"date":"2023-04-13T16:04:56","date_gmt":"2023-04-13T14:04:56","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\/"},"modified":"2023-04-13T16:04:56","modified_gmt":"2023-04-13T14:04:56","slug":"interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\/","title":{"rendered":"Interaxon Inc. (Muse\u00ae) Announces Jean-Michel Fournier as New CEO"},"content":{"rendered":"<div>\n<p>TORONTO&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/meditation?src=hash\" target=\"_blank\" rel=\"noopener\">#meditation<\/a>&#8212;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fchoosemuse.com%2F&amp;esheet=53380561&amp;newsitemid=20230413005226&amp;lan=en-US&amp;anchor=Muse&amp;index=1&amp;md5=3380557178dbe53d75a2b891d0af2c60\" rel=\"nofollow noopener\" shape=\"rect\">Muse<\/a>, the leading brain health platform built on innovative Electroencephalogram (EEG), announced that Jean-Michel Fournier has joined the company as Chief Executive Officer and member of the board. Fournier brings a wealth of experience in scaling high-growth companies and driving innovation in the health and wellness space. He succeeds Derek Luke, who now takes an advisory role.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230413005226\/en\/1762653\/5\/interaxon_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230413005226\/en\/1762653\/21\/interaxon_logo.jpg\"><\/a><\/p>\n<p>\nFournier joins Interaxon from BODi (NYSE:BODY), the leading digital wellness and nutrition subscription company, where he served as President of Corporate Development &amp; Strategic Partnerships. He also served as CEO of Les Mills Media, part of Les Mills International, one of the largest active fitness &amp; wellness communities in the world. Prior to this, Fournier was the co-founder &amp; CEO of the mobile and computer vision platform BitGym, and held several senior executive roles at UnitedHealth Group and Hewlett Packard.<\/p>\n<p>\n\u201cWe are thrilled to welcome Jean-Michel to Interaxon,\u201d said Lally Rementilla, Interaxon board chair and Managing Partner, IP-Backed Financing, BDC Capital. \u201cHis impressive track record of building and leading successful companies in the digital wellness and healthcare space, combined with his passion for using technology to improve people\u2019s lives, makes him the ideal leader to guide Interaxon through its next phase of growth.\u201d<\/p>\n<p>\n\u201cI am honored to be joining Interaxon at such an inflection point in the company\u2019s history,\u201d said Fournier. \u201cWith its patented mEEG platform, Interaxon has firmly established itself as a global leader in the brain health and neurotechnology space. I\u2019m excited to work with such a talented team to drive even greater growth and support innovation that helps millions of people to improve their mental health and well being.\u201d<\/p>\n<p>\nInteraxon\u2019s cornerstone product, The Muse headband, uses electroencephalography (EEG) sensors to monitor brain activity and provide real-time feedback to users about their mental state, including their level of focus, relaxation, and stress. The Muse headband has been used by individuals, researchers, and clinicians to improve mindfulness, mental health practices, and support neuroscience research and innovation. With Fournier at the helm, Interaxon is poised to expand its reach and impact, with a focus on developing new products and strategic partnerships that leverage the power of brain-sensing technology to address a wide range of health and wellness challenges.<\/p>\n<p>\n\u201cJean-Michel\u2019s experience and expertise in the wellness and healthcare industries will be invaluable as we continue to grow and innovate at Interaxon,\u201d said Ariel Garten, Interaxon Co-founder &amp; Chief Evangelist Officer. \u201cWe are excited to see the impact he will have on our company, our customers, and our mission of empowering people to live healthier, happier lives.\u201d<\/p>\n<p>\n<b>About Interaxon Inc.:<\/b><\/p>\n<p>\nInteraxon is a Canadian neurotechnology company specializing in developing brain computer interfaces (BCIs) and state-of-the-art experiences through the production of their research-grade EEG headbands and related software applications. The company was founded in 2007 by a team of neuroscientists, engineers, and designers with the goal of advancing neuroscience research and helping individuals build a rewarding meditation practice to live healthier, happier, more connected lives through human-centered technology.<\/p>\n<p>\nInteraxon is headquartered in Toronto, Canada and has a global reach, with customers in over 100 countries. The company has received numerous awards and accolades for its innovative technology and dedication to improving mental health and wellness.<\/p>\n<p>\nMore information is available at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.choosemuse.com&amp;esheet=53380561&amp;newsitemid=20230413005226&amp;lan=en-US&amp;anchor=www.choosemuse.com&amp;index=2&amp;md5=b852ccd099f7519d15ccc07371e6724f\" rel=\"nofollow noopener\" shape=\"rect\">www.choosemuse.com<\/a>.<\/p>\n<p>\n<b>Milestones we\u2019re excited about:<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Muse Brain Health Platform:<\/b> combines Muse\u2019s meditation and sleep headbands with personalized metrics, expert guidance, and robust content via Muse\u2019s membership, app, and community to support users on their individual wellness journey<\/li>\n<li>\n<b>Research institutions using Muse\u00ae: <\/b>The Mayo Clinic, NASA, Harvard, MIT, U of T, UCL, UCSD, Inria, UVic, UBC, and more.<\/li>\n<li>\n<b>Meditating with Muse\u00ae works:<\/b> Muse has been used in over 200 published studies, including Mayo Clinic who demonstrated meditating with Muse increases quality of life, and decreases stress and fatigue in cancer patients.<\/li>\n<li>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmeditationstudioapp.com%2Fpodcasts&amp;esheet=53380561&amp;newsitemid=20230413005226&amp;lan=en-US&amp;anchor=Untangle+Podcast&amp;index=3&amp;md5=af3970e2bc4ce8642bf8dbc267f1dd0a\" rel=\"nofollow noopener\" shape=\"rect\"><b>Untangle Podcast<\/b><\/a><b>:<\/b> With more than 11 million plays, Untangle hosts Patricia Karpas and Ariel Garten interview thought-provoking authors, experts and leaders in areas related to mindfulness, sleep, neuroscience, brain health practices, and more.<\/li>\n<\/ul>\n<p>\n\u00a0<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nMax Borges Agency<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#x69;&#x6c;t&#111;&#58;&#x6d;&#x75;s&#101;&#64;&#x6d;&#x61;x&#98;&#x6f;&#x72;&#x67;e&#115;&#x61;&#x67;e&#110;&#99;&#x79;&#x2e;c&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6d;&#x75;&#x73;&#x65;&#64;&#109;&#97;xb&#x6f;&#x72;&#x67;&#x65;&#x73;&#97;&#103;&#101;nc&#x79;&#x2e;&#x63;&#x6f;&#x6d;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>TORONTO&#8211;(BUSINESS WIRE)&#8211;#meditation&#8212;Muse, the leading brain health platform built on innovative Electroencephalogram (EEG), announced that Jean-Michel Fournier has joined the company as Chief Executive Officer and member of the board. Fournier brings a wealth of experience in scaling high-growth companies and driving innovation in the health and wellness space. He succeeds Derek Luke, who now takes &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55791","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Interaxon Inc. (Muse\u00ae) Announces Jean-Michel Fournier as New CEO - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Interaxon Inc. (Muse\u00ae) Announces Jean-Michel Fournier as New CEO - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TORONTO&#8211;(BUSINESS WIRE)&#8211;#meditation&#8212;Muse, the leading brain health platform built on innovative Electroencephalogram (EEG), announced that Jean-Michel Fournier has joined the company as Chief Executive Officer and member of the board. Fournier brings a wealth of experience in scaling high-growth companies and driving innovation in the health and wellness space. He succeeds Derek Luke, who now takes ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-13T14:04:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230413005226\/en\/1762653\/21\/interaxon_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Interaxon Inc. (Muse\u00ae) Announces Jean-Michel Fournier as New CEO\",\"datePublished\":\"2023-04-13T14:04:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\\\/\"},\"wordCount\":684,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230413005226\\\/en\\\/1762653\\\/21\\\/interaxon_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\\\/\",\"name\":\"Interaxon Inc. (Muse\u00ae) Announces Jean-Michel Fournier as New CEO - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230413005226\\\/en\\\/1762653\\\/21\\\/interaxon_logo.jpg\",\"datePublished\":\"2023-04-13T14:04:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230413005226\\\/en\\\/1762653\\\/21\\\/interaxon_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230413005226\\\/en\\\/1762653\\\/21\\\/interaxon_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Interaxon Inc. (Muse\u00ae) Announces Jean-Michel Fournier as New CEO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Interaxon Inc. (Muse\u00ae) Announces Jean-Michel Fournier as New CEO - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\/","og_locale":"en_US","og_type":"article","og_title":"Interaxon Inc. (Muse\u00ae) Announces Jean-Michel Fournier as New CEO - Pharma Trend","og_description":"TORONTO&#8211;(BUSINESS WIRE)&#8211;#meditation&#8212;Muse, the leading brain health platform built on innovative Electroencephalogram (EEG), announced that Jean-Michel Fournier has joined the company as Chief Executive Officer and member of the board. Fournier brings a wealth of experience in scaling high-growth companies and driving innovation in the health and wellness space. He succeeds Derek Luke, who now takes ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-13T14:04:56+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230413005226\/en\/1762653\/21\/interaxon_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Interaxon Inc. (Muse\u00ae) Announces Jean-Michel Fournier as New CEO","datePublished":"2023-04-13T14:04:56+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\/"},"wordCount":684,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230413005226\/en\/1762653\/21\/interaxon_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\/","url":"https:\/\/pharma-trend.com\/en\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\/","name":"Interaxon Inc. (Muse\u00ae) Announces Jean-Michel Fournier as New CEO - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230413005226\/en\/1762653\/21\/interaxon_logo.jpg","datePublished":"2023-04-13T14:04:56+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230413005226\/en\/1762653\/21\/interaxon_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230413005226\/en\/1762653\/21\/interaxon_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/interaxon-inc-muse-announces-jean-michel-fournier-as-new-ceo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Interaxon Inc. (Muse\u00ae) Announces Jean-Michel Fournier as New CEO"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55791"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55791\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55791"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55791"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}